Albert Labs CEO Dr. Michael Raymont tells Proactive it has been issued a Health Canada license enabling the possession, production, and delivery of psilocybin and other psychoactive controlled substance.
The license will allow Albert Labs' to supply product to their Real World Evidence (RWE) trial in the UK, as well as distribute and sell API to other licensed customers. Under the Special Access Program (SAP) in Canada, Albert Labs is also able, once a medicinal product is approved, to provide health care professionals with medicines under prescribed conditions.